Literature DB >> 1325952

Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.

W E Laug1, K Wang, R Mundi, W Rideout, E K Kruithof, E Bogenmann.   

Abstract

The human sarcoma cell line HT1080 was found, by in situ hybridization, to consist of cells expressing various levels of urokinase (uPA) and tissue type (tPA) plasminogen activator (PA) suggesting clonal variation of expression of these genes. Colonies originating from single HT1080 cells were, therefore, established and screened for PA activity using a fibrin agarose overlay. Colonies inducing lysis (clone C+ and H+) or no lysis (clones B- and M-) were isolated and tested for mRNA levels of uPA, tPA, uPA receptor (uPAR) and the 3 PA inhibitors (PAI), PAI-1, PAI-2 and protease-nexin I. The different clones revealed considerable variation of expression of the different PA and PAI genes, with lysis-inducing clones expressing mainly the PA genes, whereas non-lysing clones demonstrated higher expression of the PAI genes. Amplification or loss of specific genes was excluded by Southern blotting. The protein levels of cellular and secreted PA and PAI determined by ELISA and Western blots demonstrated a pattern similar to that observed for PA and PAI mRNA concentrations, suggesting clonal differences either on the level of transcription or in RNA processing and/or stability. Due to complex interactions between PA and PAI, neither mRNA nor protein levels of the different genes were predictive for the amount of functional PA activity present in the supernatant or on the cell surface of the different clones. Receptor-bound uPA activity was found to be considerably higher in lysis-inducing than in non-lysing clones and the activity was dependent on neutralization by PAI-1 rather than on the level of uPAR mRNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325952     DOI: 10.1002/ijc.2910520224

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines.

Authors:  L H Brail; R P Hill
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

2.  Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.

Authors:  D H Nguyen; A D Catling; D J Webb; M Sankovic; L A Walker; A V Somlyo; M J Weber; S L Gonias
Journal:  J Cell Biol       Date:  1999-07-12       Impact factor: 10.539

3.  Urokinase induces receptor mediated brain tumor cell migration and invasion.

Authors:  T J MacDonald; Y A DeClerck; W E Laug
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

4.  Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.

Authors:  B M Mueller; Y B Yu; W E Laug
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

5.  Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.

Authors:  D J Webb; K S Thomas; S L Gonias
Journal:  J Cell Biol       Date:  2001-02-19       Impact factor: 10.539

6.  Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.

Authors:  Khaled Shahrour; Rick Keck; Jerzy Jankun
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

7.  Effect of Regulatory Element DNA Methylation on Tissue-Type Plasminogen Activator Gene Expression.

Authors:  Sylvie Dunoyer-Geindre; Anne-Sophie Rivier-Cordey; Carlos Caetano; Richard J Fish; Egbert K O Kruithof
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

8.  Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.

Authors:  Wayne A Schroder; Lee D Major; Thuy T Le; Joy Gardner; Matthew J Sweet; Sabina Janciauskiene; Andreas Suhrbier
Journal:  Cancer Med       Date:  2014-03-19       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.